Autolus is a biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies aimed at treating cancer. The company leverages advanced T cell programming technologies to engineer therapies that precisely target and control the immune system to recognize, attack, and destroy cancer cells. Autolus focuses on both hematological cancers and solid tumors, offering substantial benefits over existing standard-of-care treatments. The company primarily serves patients with relapsed or refractory cancers, particularly those who have not responded to conventional therapies. Operating in the biopharmaceutical market, Autolus employs a business model centered around research and development, clinical trials, and eventual commercialization of its proprietary therapies. Revenue is generated through partnerships, licensing agreements, and future sales of approved therapies.

Keywords: T cell therapy, cancer treatment, biopharmaceutical, hematological cancers, solid tumors, immune system, precision medicine, clinical trials, CAR T cell, next-generation therapies.